Please login to the form below

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

UK approval for Seagen’s oral HER2 inhibitor Tukysa

In 2019, Seagen announced that it had initiated another trial of Tukysa – the HER2CLIMB-02 study – that will compare Tukysa to placebo in combination with Kadcyla (ado-trastuzumab emtansine) in

Latest news

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

trastuzumab emtansine). ... Trastuzumab deruxtecan is central to Daiichi’s growth efforts, and is also a key drug for AZ’s cancer franchise.
Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... ado-trastuzumab emtansine).
Roche posts minor sales miss in Q4 as biosimilar pressure grows

Looking forward to this year and beyond, additional indications for Tecentriq and HER2-positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) will also help drive future growth, said Roche, although ... the latter is facing new
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... Perjeta (pertuzumab) and Kadcyla
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

The EMA has cleared Kadcyla (ado-trastuzumab emtansine) for the adjuvant or post-surgery treatment of adults with HER2-positive early breast cancer, who still have some residual signs of invasive ... cancer cells despite treatment before surgery with

More from news
Approximately 5 fully matching, plus 53 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Roche already has a somewhat underperforming trastuzumab-based ADC in the form of Kadcyla (trastuzumab emtansine)
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Are biobetters a market access opportunity?

trastuzumab emtansine), received its first EU approval. for HER2+ metastatic breast cancer patients who did not respond to Herceptin and/or taxane.
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Roche’s Kadcyla (trastuzumab emtansine). the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Executive: Competitive Salary

Account Manager: Competitive Salary

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Medical Editor: Competitive Salary

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Medical Writer: Competitive Salary

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Associate Account Director: Competitive Salary

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Content Editor - Biotechnology: Salary TBC

No results were found

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Empowering patients empowers results: Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials: What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training: Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...